WallStSmart

Baidu Inc (BIDU)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Baidu Inc generates 414% more annual revenue ($129.08B vs $25.12B). SYK leads profitability with a 12.9% profit margin vs 4.3%. BIDU appears more attractively valued with a PEG of 0.66. SYK earns a higher WallStSmart Score of 65/100 (C+).

BIDU

Hold

46

out of 100

Grade: D+

Growth: 4.7Profit: 4.0Value: 4.7Quality: 7.0
Piotroski: 2/9Altman Z: 2.40

SYK

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BIDUSignificantly Overvalued (-1147.8%)

Margin of Safety

-1147.8%

Fair Value

$11.63

Current Price

$115.60

$103.97 premium

UndervaluedFair: $11.63Overvalued
SYKUndervalued (+16.8%)

Margin of Safety

+16.8%

Fair Value

$393.59

Current Price

$327.65

$65.94 discount

UndervaluedFair: $393.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIDU2 strengths · Avg: 9.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

PEG RatioValuation
0.668/10

Growing faster than its price suggests

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$125.72B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

Areas to Watch

BIDU4 concerns · Avg: 3.0/10
Return on EquityProfitability
1.9%3/10

ROE of 1.9% — below average capital efficiency

Profit MarginProfitability
4.3%3/10

4.3% margin — thin

Operating MarginProfitability
4.5%3/10

Operating margin of 4.5%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

SYK3 concerns · Avg: 3.7/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BIDU

The strongest argument for BIDU centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.

Bear Case : BIDU

The primary concerns for BIDU are Return on Equity, Profit Margin, Operating Margin. A P/E of 65.8x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

SYK carries more volatility with a beta of 0.87 — expect wider price swings.

SYK is growing revenue faster at 11.4% — sustainability is the question.

SYK generates stronger free cash flow (1.9B), providing more financial flexibility.

Monitor INTERNET CONTENT & INFORMATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (65/100 vs 46/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baidu Inc

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · China

Baidu, Inc. provides Internet search services primarily in China. The company is headquartered in Beijing, China.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?